Joshua F. Coleman
No Rating Available
(Learn About Our Rating System)

Joshua F. Coleman, MD

Languages spoken: English

Specialties

  • Pathology, Anatomical

Board Certification

American Board of Pathology (Anatomic & Clinical)
American Board of Pathology (Sub: Molecular Genetic Pathology)
American Board of Pathology (Sub: Hematology)

Board Certification and Academic Information

Academic Departments Pathology -Associate Professor (Clinical)
Board Certification
American Board of Pathology (Anatomic & Clinical)
American Board of Pathology (Sub: Molecular Genetic Pathology)
American Board of Pathology (Sub: Hematology)

Education history

Undergraduate Preprofessional Studies - University of Notre Dame B.S.
Professional Medical Medicine - Case Western Reserve University School of Medicine M.D.
Residency Anatomic and Clinical Pathology - Pathology & Laboratory Medicine Institute, Cleveland Clinic Resident
Chief Resident Anatomic Pathology - Pathology & Laboratory Medicine Institute, Cleveland Clinic Chief Resident
Fellowship Hematopathology - University of New Mexico School of Medicine Fellow
Fellowship Molecular Genetic Pathology - ARUP Laboratories/University of Utah Fellow

Selected Publications

Journal Article

  1. Sirohi D, Schmidt RL, Aisner DL, Behdad A, Betz BL, Brown N, Coleman JF, Corless CL, Deftereos G, Ewalt MD, Fernandes H, Hsiao SJ, Mansukhani MM, Murray SS, Niu N, Ritterhouse LL, Suarez CJ, Tafe LJ, Thorson JA, Segal JP, Furtado L (2020). Multi-Institutional Evaluation of Interrater Agreement of Variant Classification Based on the 2017 Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. The Journal of molecular diagnostics, 22(2), 284-293.
  2. Wilcock DM, Sirohi D, Coleman JF, Gulbahce H (2022). Digital imaging correlation of immunohistochemistry and fluorescence in situ hybridization in breast carcinoma cases with HER2 genetic heterogeneity. Human pathology, 126, 129-135.
  3. Wilcock DM, McMurtry V, Coleman JF, Kim JT, Khalili P, Deftereos G, Albertson D, Gulbahce EH, Liu T, Sirohi (2022). Histopathological Correlation of Chromosome 12 Polysomy by Fluorescence in Situ Hybridization in Adipocytic Neoplasms. International journal of surgical pathology, 30(7), 734-742.
  4. Lin L, Sirohi D, Coleman JF, Gulbahce H (2019). American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing Guidelines: Results From a National Reference Laboratory. American journal of clinical pathology, 152(4), 479-485.
  5. Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Burlingame J, Davis R, Affolter K, Albertson DJ, Adelhardt P, Kim JT, Coleman JF, Deftereos G, Gulbahce EH, Sirohi (2023). Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast Cancer. Archives of pathology & laboratory medicine,
  6. McMurtry V, Mahlow J, Coleman JF, Deftereos G, Jattani R, Bastien RRL, Durtschi J, Jarboe E, Lomo L, Sirohi (2023). Morphologic Characteristics and Mutational Analysis of Fumarate Hydratase Deficient Kidney and Smooth Muscle Tumors. American journal of clinical pathology, 159(2), 164-171.
  7. Wilcock D, Sirohi D, Albertson D, Cleary AS, Coleman JF, Jedrzkiewicz J, Mahlow J, Ruano AL, Gulbahce H (2024). Clinicopathologic Features of 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 Breast Carcinoma (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ¿6.0). Archives of pathology & laboratory medicine, 148(8), 890-897.
  8. Wilcock D, Sirohi D, Coleman JF, Adelhardt P, Kim JT, Albertson D, Affolter K, Beech C, Jedrzkiewicz J, Ruano AL, Cleary AS, Mahlow J, Balatico M, Gulbahce H (2025). HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry. American journal of clinical pathology, 163(6), 837-846.
  9. Beech C, Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Davis R, Affolter K, Albertson DJ, Adelhardt P, Kim J, Coleman JF, Deftereos G, Gulbahce EH, Sirohi (2025). Changes in HER2 Amplification Status for Breast Cancer Patients After Immunohistochemistry Directed In Situ Hybridization. Applied immunohistochemistry & molecular morphology, 33(2), 91-102.
  10. Yilmaz A, Frankel WL, Zhao W, Suarez AA, Chen W, Coleman JF, McElroy JP, Pearlman R, Goodfellow PJ, Hampel (2025). Instability in the Penta-C and Penta-D Loci in Microsatellite-Unstable Endometrial Cancer. International journal of environmental research and public health, 22(11),
  11. Yilmaz A, Frankel WL, Zhao W, Suarez AA, Chen W, Coleman JF, McElroy JP, Pearlman R, Goodfellow PJ, Hampel (2025). Instability in the Penta-C and Penta-D Loci in Microsatellite-Unstable Endometrial Cancer. International journal of environmental research and public health, 22(11),

Review

  1. Duncavage EJ, Coleman JF, de Baca ME, Kadri S, Leon A, Routbort M, Roy S, Suarez CJ, Vanderbilt C, Zook J (2023). Recommendations for the Use of in Silico Approaches for Next-Generation Sequencing Bioinformatic Pipeline Validation: A Joint Report of the Association for Molecular Pathology, Association for Pathology Informatics, and College of American Pathologists. The Journal of molecular diagnostics, 25(1), 3-16.
  2. Coleman J (2023). Computer-Based Simulation of DNA Short-Read Next-Generation Sequencing: A Review of Software from a Clinical Perspective. Advances in Molecular Pathology, 6(1), 125-138.
  3. Leon A, Castro-Echeverry E, Fussell AM, Jordan D, Kip NS, Roy A, Suarez CJ, Temple-Smolkin RL, Coleman (2025). Clinical Bioinformatician Body of Knowledge-Molecular Diagnostics Core: A Report of the Association for Molecular Pathology. The Journal of molecular diagnostics, 27(7), 546-565.

Letter

  1. Gulbahce HE, Coleman JF, Sirohi (2019). Interference of Tissue-Marking Dyes With Fluorescence In Situ Hybridization Assays. Archives of pathology & laboratory medicine, 143(11), 1299.